Aveanna Healthcare Holdings Inc. (AVAH)
| Market Cap | 2.88B +57.6% |
| Revenue (ttm) | 2.60B +19.5% |
| Net Income | 274.76M +1,380.8% |
| EPS | 1.23 +1,199.5% |
| Shares Out | 218.22M |
| PE Ratio | 10.71 |
| Forward PE | 15.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,898,040 |
| Open | 13.34 |
| Previous Close | 13.25 |
| Day's Range | 13.17 - 13.58 |
| 52-Week Range | 5.93 - 14.71 |
| Beta | 2.01 |
| Analysts | Buy |
| Price Target | 15.05 (+14.02%) |
| Earnings Date | Nov 12, 2026 |
About AVAH
Aveanna Healthcare Holdings Inc., a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities. The company operates through three segments: Private Duty Services (PDS), Home Health & Hospice (HHH), and Medical Solutions (MS). The PDS segment offers private duty nursing (PDN) services, which include in... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for AVAH stock is "Buy." The 12-month stock price target is $15.05, which is an increase of 14.02% from the latest price.
News
Aveanna Announces Third Quarter 2026 Earnings Release Date and Conference Call
ATLANTA, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its third quarter results before the market open on...
Aveanna Healthcare Holdings Transcript: Deutsche Bank 2026 Healthcare Summit
A multi-year transformation driven by preferred payer strategies and operational efficiency has led to significant growth, margin improvement, and a strengthened balance sheet. Expansion into new states, a major California rate win, and continued M&A are set to fuel further growth through 2028.
Aveanna Healthcare Holdings Transcript: 2026 Jefferies Healthcare Services and Technology Conference
Strong Q2 results and updated long-term growth outlook are supported by state rate wins and preferred payer expansion. Free cash flow and deleveraging remain priorities, with disciplined M&A focused on home health. Guidance for H2 is consistent, with continued operational efficiency and growth.
Aveanna price target raised to $15 from $8 at JPMorgan
JPMorgan raised the firm’s price target on Aveanna (AVAH) to $15 from $8 and keeps a Neutral rating on the shares. The firm updated the company’s model. Published first on…
Aveanna price target raised to $15 from $9.50 at Barclays
Barclays raised the firm’s price target on Aveanna (AVAH) to $15 from $9.50 and keeps an Overweight rating on the shares. The firm updated models in the healthcare facilities and…
Aveanna to Participate in the Deutsche Bank 2026 Healthcare Summit
ATLANTA, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the Deutsche Bank 2026 Healthcare Summit in ...
Aveanna to Participate in the 2026 Jefferies Healthcare Services and Technology Conference
ATLANTA, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the 2026 Jefferies Healthcare Services and T...
Aveanna price target raised to $15 from $11 at Truist
Truist raised the firm’s price target on Aveanna (AVAH) to $15 from $11 and keeps a Hold rating on the shares. The firm is updating its estimates to reflect the…
Aveanna price target raised to $16 from $10 at RBC Capital
RBC Capital raised the firm’s price target on Aveanna (AVAH) to $16 from $10 and keeps an Outperform rating on the shares. The firm notes that it was pleased to…
Aveanna price target raised to $16 from $10 at RBC Capital
RBC Capital raised the firm’s price target on Aveanna (AVAH) to $16 from $10 and keeps an Outperform rating on the shares.
Aveanna Announces Pricing of Secondary Offering of Common Stock
ATLANTA, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient ...
Aveanna announces offering of 15M shares of common stock for holders
Aveanna (AVAH) Healthcare Holdings announced that certain selling stockholders, including affiliates of J.H. Whitney Equity Partners VII, and certain current and former directors and officers of the c...
Aveanna Announces Launch of Secondary Offering of Common Stock
ATLANTA, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient ...
Aveanna reports Q2 EPS 18c, consensus 17c
Reports Q2 revenue $670.48M, consensus $639.63M. Jeff Shaner, Chief Executive Officer, commented, “Our second quarter results demonstrate the momentum across Aveanna (AVAH) and our ability to consiste...
Aveanna backs FY26 revenue view $2.63B-$2.65B, consensus $2.63B
Raises FY26 adjusted EBITDA view to greater than $365M from $338M-$342M. Matt Buckhalter, Chief Financial Officer, commented “Aveanna’s (AVAH) second quarter results continued our momentum with our te...
Aveanna price target raised to $14 from $10 at BMO Capital
BMO Capital raised the firm’s price target on Aveanna (AVAH) to $14 from $10 and keeps an Outperform rating on the shares. The company delivered another beat-and-raise with Q2 revenue…
Aveanna price target raised to $13 from $8 at UBS
UBS raised the firm’s price target on Aveanna (AVAH) to $13 from $8 and keeps a Neutral rating on the shares. The firm updated its model to reflect Aveanna’s updated…
Aveanna price target raised to $15 from $13 at Raymond James
Raymond James raised the firm’s price target on Aveanna (AVAH) to $15 from $13 and keeps a Strong Buy rating on the shares. Aveanna’s Q2 EBITDA beat and higher guidance…
Aveanna price target raised to $16 from $11.50 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Aveanna (AVAH) to $16 from $11.50 and keeps a Buy rating on the shares.
Aveanna Healthcare Holdings Earnings Call Transcript: Q2 2026
Q2 2026 saw 13.7% revenue growth and 8% adjusted EBITDA growth, driven by strong segment performance, preferred payer strategies, and operational efficiencies. Guidance for 2026 was raised, with long-term growth rates increased for core segments and continued focus on M&A and deleveraging.
Aveanna Healthcare Holdings Earnings release: Q2 2026
Aveanna Healthcare Holdings released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Aveanna Healthcare Holdings Quarterly report: Q2 2026
Aveanna Healthcare Holdings has published its Q2 2026 quarterly earnings report on August 13, 2026.
Aveanna Healthcare Holdings Slides: Investor presentation
Aveanna Healthcare Holdings has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Aveanna Healthcare Holdings Announces Second Quarter Financial Results and Revised 2026 Guidance
Second Quarter Revenue was $670.5 million, a 13.7% increase over the prior year period Second Quarter Net income was $40.3 million compared to $27.0 million for the prior year period Adjusted EBITDA f...
Aveanna Announces Second Quarter 2026 Earnings Release Date and Conference Call
ATLANTA, July 23, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that the company will release its second quarter results before the market open o...